P/E at 34.6 vs Industry's 33.3: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Amidst Sector Norms

The current P/E ratio of 34.6 for Sun Pharmaceutical Industries Ltd represents a modest premium of approximately 4% over the industry average of 33.3. This premium suggests that investors are willing to pay slightly more for the stock relative to its sector peers, reflecting expectations of either superior earnings quality or growth prospects. However, the premium is not excessive, indicating a valuation that remains broadly in line with sector norms. Sun Pharma's market capitalisation stands at ₹4,19,332 crores, categorising it firmly as a large-cap stock within the Pharmaceuticals & Biotechnology sector.

Performance Across Timeframes: Divergent Momentum

Examining the stock’s returns reveals a nuanced performance profile. Over the past year, Sun Pharmaceutical Industries Ltd has declined by 2.44%, slightly outperforming the Sensex’s 3.87% fall. This relative resilience is notable given the broader market weakness. However, the short-term momentum tells a different story. The stock has gained 10.78% over the last three months, significantly outperforming the Sensex’s 6.52% decline in the same period. This sharp divergence between medium-term strength and longer-term weakness raises questions about the sustainability of recent gains — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

In the one-month timeframe, the stock has slipped 1.95%, underperforming the Sensex’s 4.89% gain, while the year-to-date return is a modest 2.38%, contrasting with the Sensex’s 9.43% decline. The one-week performance is particularly strong, with a 5.48% gain against the Sensex’s 1.70% loss, highlighting recent positive momentum. The stock has also recorded a three-day consecutive gain streak, rising 8.52% in that period, signalling short-term bullishness.

Moving Average Configuration: Bullish Across All Key Levels

The technical picture for Sun Pharmaceutical Industries Ltd is notably constructive. The stock is trading above all major moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This configuration typically indicates a strong uptrend and suggests that recent price action has overcome previous resistance levels. Such a setup often reflects sustained buying interest and can be a precursor to further gains. However, given the mixed performance across different timeframes, is this momentum likely to continue or is it a short-lived bounce?

Sector Performance Context: Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen mixed results recently. Of the two stocks that have declared results so far, both reported positive outcomes, with none flat or negative. This suggests a generally favourable environment for the sector, which may be supporting Sun Pharmaceutical Industries Ltd’s relative outperformance in certain periods. The sector’s resilience could be a factor in the stock’s ability to maintain a valuation premium over the industry average.

Rating Reassessment: Previously Hold, Now Updated

Sun Pharmaceutical Industries Ltd was previously rated Hold by MarketsMOJO before its rating was reassessed on 27 Apr 2026. While the current rating is not disclosed, the reassessment reflects a fresh evaluation of the company’s fundamentals, valuation, and technicals. The previous Hold rating was based on a Mojo Score of 72.0, indicating a solid but not unequivocal investment case. What is the current rating and how does it reflect the recent performance and valuation data?

Long-Term Performance: A Mixed Legacy

Looking beyond the recent year, Sun Pharmaceutical Industries Ltd has delivered strong returns over the medium to long term. The three-year return stands at 78.43%, significantly outperforming the Sensex’s 26.30%. Over five years, the stock has surged 173.15%, compared to the Sensex’s 55.09%. However, the ten-year return of 117.02% trails the Sensex’s 201.42%, indicating that while the stock has been a strong performer in recent years, it has lagged the broader market over the last decade. This long-term perspective adds nuance to the current valuation premium and recent performance trends.

Conclusion: A Stock Balancing Valuation and Momentum

The data on Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading at a modest premium to its sector, supported by a strong technical setup and mixed but generally resilient performance across timeframes. The recent three-month surge contrasts with a slight one-year decline, while the stock’s position above all key moving averages signals underlying strength. The sector’s positive results and the company’s previous Hold rating, now reassessed, add further layers to the analysis — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today